Tyra Biosciences price target raised to $42 from $33 at Piper Sandler

Piper Sandler raised the firm’s price target on Tyra Biosciences (TYRA) to $42 from $33 and keeps an Overweight rating on the shares. The firm says Tyra remains a top pick for 2026. Piper believes lead asset dabogratinib is potentially best in class with application across three high-value indications driven by FGFR3 alterations, namely achondroplasia, IR-NMIBC, and LG-UTUC. While the stock has outperformed recently, the firm sees significant upside remaining as the company approaches key de-risking clinical catalysts in IR-NMIBC and achondroplasia.